JP2022526495A - 胃腸疾患および障害を治療するための組成物およびその方法 - Google Patents

胃腸疾患および障害を治療するための組成物およびその方法 Download PDF

Info

Publication number
JP2022526495A
JP2022526495A JP2021556420A JP2021556420A JP2022526495A JP 2022526495 A JP2022526495 A JP 2022526495A JP 2021556420 A JP2021556420 A JP 2021556420A JP 2021556420 A JP2021556420 A JP 2021556420A JP 2022526495 A JP2022526495 A JP 2022526495A
Authority
JP
Japan
Prior art keywords
rifaximin
antibiotics
mucolytic agent
nac
ibs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526495A5 (cg-RX-API-DMAC10.html
Inventor
ピメンタル，マーク
ギマラエス ソウサ レイテ，ガブリエラ
メイサー，ルチ
レザイエ，アリ
モラレス，ウォルター
ワイツマン，ステイシー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars-Sinai Medical Center
Original Assignee
Cedars-Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars-Sinai Medical Center filed Critical Cedars-Sinai Medical Center
Publication of JP2022526495A publication Critical patent/JP2022526495A/ja
Publication of JP2022526495A5 publication Critical patent/JP2022526495A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021556420A 2019-03-18 2020-03-18 胃腸疾患および障害を治療するための組成物およびその方法 Pending JP2022526495A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819986P 2019-03-18 2019-03-18
US62/819,986 2019-03-18
PCT/US2020/023396 WO2020191076A1 (en) 2019-03-18 2020-03-18 Compositions and methods to treat gastrointestinal diseases and disorders

Publications (2)

Publication Number Publication Date
JP2022526495A true JP2022526495A (ja) 2022-05-25
JP2022526495A5 JP2022526495A5 (cg-RX-API-DMAC10.html) 2023-03-14

Family

ID=72520533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556420A Pending JP2022526495A (ja) 2019-03-18 2020-03-18 胃腸疾患および障害を治療するための組成物およびその方法

Country Status (7)

Country Link
US (1) US12642793B2 (cg-RX-API-DMAC10.html)
EP (1) EP3941461A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022526495A (cg-RX-API-DMAC10.html)
CN (1) CN113645968A (cg-RX-API-DMAC10.html)
AU (2) AU2020240069B2 (cg-RX-API-DMAC10.html)
CA (2) CA3132400C (cg-RX-API-DMAC10.html)
WO (1) WO2020191076A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3132400C (en) 2019-03-18 2026-05-12 Cedars-Sinai Medical Center Compositions and methods to treat gastrointestinal diseases and disorders
EP4510915A4 (en) * 2022-04-20 2026-01-21 Cedars Sinai Medical Center METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) AND SELECTING AN ANTI-IBS-D TREATMENT
JP2025516807A (ja) * 2022-05-19 2025-05-30 シーダーズ－サイナイ メディカル センター リファキシミンとｎ－アセチルシステインの製剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264409A1 (en) * 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
JP2016520108A (ja) * 2013-05-29 2016-07-11 ザンボン ソシエタ ペル アチオニ 嚥下可能なｎ−アセチルシステイン錠剤
JP2017520624A (ja) * 2014-06-30 2017-07-27 サリックス ファーマスーティカルズ，インコーポレーテッド 過敏性腸症候群（ｉｂｓ）を再治療するための方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1235529A (en) * 1968-12-02 1971-06-16 Calbiochem Composition for mucolysis
ES392136A1 (es) 1971-06-11 1973-03-01 Espanola Prod Quimicos Un procedimiento de obtencion de una sal de doxiciclina.
IT1134458B (it) 1980-11-26 1986-08-13 Real Sas Di Alberto Reiner Derivato della n-acetil-cisteina ad attivita' terapeutica,procedimento per la sua preparazione e relative composizioni farmaceutiche
IT1141959B (it) 1981-01-27 1986-10-08 Istituto Biochimico Italiano Nuovi sali ad attivita' antibiotica e mucolitica
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
TWI236905B (en) * 1997-10-28 2005-08-01 Jens Ponikau Pharmaceutical composition for treating and preventing inflammation of mucosal tissue
WO2000023081A1 (en) 1998-10-20 2000-04-27 Lauteral Limited Derivatives of erythromycin, clarithromycin, roxithromycin or azithromycin with antibiotic and mucolytic activity
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20080194456A1 (en) * 2004-04-09 2008-08-14 The General Hospital Corporation Compositions And Methods Related To An Intestinal Inflammation And Uses Therefor
CN101039701A (zh) * 2004-08-26 2007-09-19 尼古拉斯皮拉马尔印度有限公司 含有生物可裂解二硫化物连接物的前药和共药
WO2008002971A2 (en) * 2006-06-29 2008-01-03 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
MXPA06014635A (es) 2006-12-14 2008-11-26 Senosiain S A De C V Lab Composicion farmaceutica que contiene una combinacion de antibiotico y mucolitico y su uso.
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
GB0823472D0 (en) * 2008-12-23 2009-01-28 Photocure Asa Product
US9408393B2 (en) 2010-02-03 2016-08-09 Microbion Corporation Bismuth-thiols as antiseptics for agricultural, industrial and other uses
GB0905451D0 (en) 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
AU2011212941B2 (en) * 2010-02-03 2016-03-03 Microbion Corporation Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
BR112015004165A2 (pt) 2012-08-29 2017-07-04 Salix Pharmaceuticals Inc métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas
WO2014036445A2 (en) * 2012-08-31 2014-03-06 Johnson Michael R Novel mucolytic agents
CN104812369B (zh) 2012-10-26 2017-11-24 心悦生医股份有限公司 壳核粒子与其制造方法以及含有壳核粒子的组合物
CA3153463A1 (en) 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
EP2991649B1 (en) 2013-04-30 2020-06-03 Thomas Julius Borody Compositions for treating obsessive-compulsive disorder
US20160158262A1 (en) * 2013-07-26 2016-06-09 Cedars-Sinai Medical Center Methods of treating irritable bowel syndrome
US10953070B2 (en) * 2014-07-25 2021-03-23 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
RU2737891C2 (ru) * 2015-04-30 2020-12-04 Пробиотикал С.П.А Применение антибиотиков со специфичными терапевтическими активностями в комбинации с одновременным применением лактобацилл и/или бифидобактерий с непередающейся устойчивостью к антибиотикам, имеющих такое же терапевтическое показание
WO2017210428A1 (en) 2016-06-01 2017-12-07 Crestovo Llc Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders
GB201621447D0 (en) 2016-12-16 2017-02-01 Novabiotics Ltd Use
CA3055311A1 (en) * 2017-02-07 2018-08-16 Stc.Unm Isotope enhanced ambroxol for long lasting autophagy induction
WO2018174839A1 (en) 2017-03-18 2018-09-27 Nguyen Mark Quang Cysteine, n-acetylcysteine and penicillamine prodrugs, pharmaceutical compositions thereof, and methods of use
JP2020513041A (ja) 2017-04-10 2020-04-30 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 病原体の阻害および／または粘液の改変のための化合物、組成物、および方法
KR20200060424A (ko) 2017-09-20 2020-05-29 아토픽 메디컬, 엘엘씨. 호흡기 질환 및 점막 염증의 치료 및 개선을 위한 조성물 및 방법
US20220186281A1 (en) 2019-01-30 2022-06-16 Cedars-Sinai Medical Center Method for processing and analysis of viscous liquid biological samples
CA3132400C (en) 2019-03-18 2026-05-12 Cedars-Sinai Medical Center Compositions and methods to treat gastrointestinal diseases and disorders
JP2025516807A (ja) 2022-05-19 2025-05-30 シーダーズ－サイナイ メディカル センター リファキシミンとｎ－アセチルシステインの製剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264409A1 (en) * 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
JP2016520108A (ja) * 2013-05-29 2016-07-11 ザンボン ソシエタ ペル アチオニ 嚥下可能なｎ−アセチルシステイン錠剤
JP2017520624A (ja) * 2014-06-30 2017-07-27 サリックス ファーマスーティカルズ，インコーポレーテッド 過敏性腸症候群（ｉｂｓ）を再治療するための方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOMED. PAPERS, vol. 148, no. 2, JPN6024007359, 2004, pages 131 - 133, ISSN: 0005412307 *
中南薬学, vol. 5, no. 4, JPN6024007358, 2007, pages 296 - 299, ISSN: 0005412306 *

Also Published As

Publication number Publication date
CA3132400A1 (en) 2020-09-24
EP3941461A4 (en) 2022-12-14
CA3132400C (en) 2026-05-12
AU2025271108A1 (en) 2025-12-18
US20230038019A1 (en) 2023-02-09
US12642793B2 (en) 2026-06-02
AU2020240069B2 (en) 2025-08-28
EP3941461A1 (en) 2022-01-26
CA3293273A1 (en) 2026-03-02
WO2020191076A1 (en) 2020-09-24
CN113645968A (zh) 2021-11-12
AU2020240069A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
KR101801864B1 (ko) 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
TW202128183A (zh) 用於治療多種病症之方法及組成物
US20090252708A1 (en) Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof
AU2025271108A1 (en) Compositions and methods to treat gastrointestinal diseases and disorders
TW201521718A (zh) 低頻率格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之治療
RU2540513C2 (ru) Способы лечения печеночной энцефалопатии
KR20150132214A (ko) 방사선 직장ｓ상결장염의 치료를 위한 조성물 및 방법
JPH06501937A (ja) 非炎症性及び非感染性腸障害の処置
RU2672871C2 (ru) Применение левоцетиризина и монтелукаста при лечении травматических повреждений
EP1796710A2 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
RU2705097C2 (ru) Применение левоцетиризина и монтелукаста при лечении анафилаксии
Sykes Antimicrobial drug use in dogs and cats
JP2016525138A (ja) 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
Birkinshaw et al. Necrotising fasciitis as a complication of steroid injection.
RU2571268C2 (ru) Модуляция системного воздействия рифаксимина
JP2021535106A (ja) 消化管障害および喘息の処置におけるガボキサドールの使用
Sykes et al. Antimicrobial Therapy in Dogs and Cats
JP7763751B2 (ja) リファキシミン液体製剤
JP2024541570A (ja) 内臓痛の処置のための医薬組成物
HK40064209A (en) Compositions and methods to treat gastrointestinal diseases and disorders
RU2297835C1 (ru) Препарат для лечения неинфекционных воспалительных болезней кишечника
US12337025B2 (en) Mutated e. coli enterotoxins as anti-inflammatory agents
Mero et al. Short-term tolerability of morniflumate in patients with cutaneous hypersensitivity reactions to non-steroidal anti-inflammatory drugs
TW202448432A (zh) 肌萎縮性側索硬化症（ａｌｓ）的治療
US20080159987A1 (en) Use of Rifaximin for the Treatment of Restless Legs Syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250408